Most people researching iboga encounter the same claim: it works differently from anything else.

That it doesn't just suppress symptoms, it resets "something". Here you will read exactly what it resets.

People come out the other side feeling neurologically and psychologically different in a way that other treatments have never produced.

There is a growing body of research that explains, mechanistically, why iboga produces effects that no other substance or therapy has been able to replicate.

Understanding the science won't make the decision for you, but it will help you understand what you're actually considering, and why the word 'reset' keeps appearing in every honest account of this medicine.

One of the most persistent and damaging myths about addiction is that it is primarily a matter of willpower or character.

The reality is that opioid addiction, particularly fentanyl dependence, produces profound and lasting changes to the brain's physical structure and chemistry.

Opioids bind to mu-opioid receptors throughout the brain and body. With sustained use, the brain responds by downregulating, reducing the number and sensitivity of these receptors.

It also suppresses its own natural production of dopamine, endorphins, and other neurochemicals that produce feelings of pleasure, motivation, and wellbeing.

The result is a brain that has been, in a very literal sense, rewired around the substance. Without it, nothing feels good. Withdrawal is not just uncomfortable, it is the nervous system screaming in a language it has learned to depend on.

This is not a failure of character. It is a neurological state. And it is precisely here that iboga acts.

Iboga's most documented and remarkable property is its ability to virtually eliminate opioid withdrawal symptoms, often completely, in a matter of hours. For people who have experienced withdrawal, this claim sounds impossible. It is not.

Iboga acts on multiple opioid receptor subtypes simultaneously. It binds to kappa and mu-opioid receptors, as well as to NMDA receptors involved in the development of physical dependence.

This multi-site action effectively resets opioid receptor sensitivity, returning the receptors toward a pre-addiction baseline in a way that no other single intervention achieves.

The result reported consistently by participants and observed in clinical settings: physical withdrawal symptoms that would otherwise last 5 to 10 days of intense suffering are interrupted within hours.

This is not suppression, the way methadone suppresses withdrawal by substituting one opioid for another. It is an actual reset of the receptor system that had become dependent.

"In 2006, researchers at the University of California, San Francisco made a discovery that shifted how scientists think about ibogaine: it dramatically stimulates the release of GDNF."

GDNF: Glial Cell Line-Derived Neurotrophic Factor is a protein that supports the survival, maintenance, and renewal of dopaminergic neurons. These are the neurons in the brain's reward pathways that are most damaged by chronic opioid use. GDNF does not just support existing neurons, it promotes the repair and regeneration of neurons that have been compromised.

To understand why this matters, consider what long-term opioid use does to the dopamine system. The brain's capacity to produce and respond to dopamine, the neurotransmitter most associated with motivation, pleasure, and the ability to feel good about ordinary life is systematically degraded.

This is why people in early recovery from opioids often describe a grey, flat, motivationless world. Their dopamine pathways have been damaged. They are not being dramatic. Their brain has structurally lost some of its capacity for natural reward.

Iboga's stimulation of GDNF release initiates a process of repair that goes beyond symptom management.

It begins to reverse the neurological damage caused by addiction, rebuilding the brain's capacity for natural dopamine function. No other addiction treatment has demonstrated this mechanism.

Alongside GDNF, iboga stimulates significant release of BDNF: Brain-Derived Neurotrophic Factor 

Where GDNF is primarily relevant to dopaminergic neurons, BDNF has a broader role: it supports neuroplasticity, the brain's ability to form new connections, strengthen new pathways, and weaken old ones.

This is the neurological basis of what participants describe as the iboga experience's most distinctive quality: the ability to look at deeply ingrained patterns, beliefs, and emotional responses with new eyes, and to feel, in the aftermath, that those patterns have genuinely loosened.

Addiction, trauma, and depression all involve neural circuits that have become rigidly entrenched, pathways that fire automatically, responses that have become reflexive rather than chosen.

BDNF creates the conditions for these circuits to be restructured. Combined with the psychological work done during and after the treatment, this neuroplasticity window is one of the most important mechanisms underlying iboga's therapeutic potential.

What makes iboga genuinely unique is not any single mechanism, it is the simultaneous action across multiple neurological systems:

• Opioid receptors: reset toward pre-dependence baseline, interrupting physical withdrawal and reducing cravings
• Dopamine pathways: GDNF-mediated repair of neurons damaged by chronic opioid use
• Serotonin system: iboga inhibits serotonin reuptake, contributing to the introspective, emotionally accessible quality of the experience
• Sigma receptors: action here is associated with anti-depressant and neuroprotective effects
• NMDA receptors: involved in the interruption of physical dependence and the disruption of entrenched behavioral patterns
• Neuroplasticity: BDNF-stimulated opening of a window for genuine neural rewiring

No pharmaceutical antidepressant, no medication-assisted treatment, no other psychedelic substance acts across all of these systems simultaneously.

This is the mechanistic basis for why iboga produces results that other treatments cannot and why people who have tried everything else sometimes find, in iboga, something that finally reaches the root.

The neurological effects of iboga are not instantaneous, they unfold over the course of the experience, with different systems responding at different rates.

This is one of the reasons our 12-hour titration protocol matters beyond just cardiac safety.

By building the medicine slowly over 12 hours, beginning with a small test dose and incrementally increasing, we allow each person's nervous system to move through the experience at a pace calibrated to their individual physiology.

The experience is not compressed into a sudden peak but allowed to unfold in layers. This produces a more complete, more integrated neurological reset and a more navigable, meaningful inner experience.

The rapid single-dose approach used by many providers prioritizes speed over depth. Our approach prioritizes depth over speed. These are different philosophies with different outcomes.

Iboga research is growing and will continue to grow now that the Schedule I status in the United States has been removed. A classification that had severely restricted formal clinical trials despite decades of compelling evidence.

The most robust human data comes from observational studies at ibogaine clinics in countries where it is legal, combined with a growing number of peer-reviewed animal studies and mechanistic research. I'm excited that America will now be on that growing list.

What the research consistently shows: dramatic reduction of opioid withdrawal symptoms, significant reduction in cravings at 30-day follow-up, GDNF and BDNF stimulation, and high rates of participant-reported long-term change in substance use patterns.

What the research cannot yet fully quantify: the role of the psychological experience itself, the life review, the emotional processing, the confrontation with one's own patterns, in producing lasting change.

Here at Entheos our observation, supported by the accounts of every participant we have worked with, is that this dimension is inseparable from the neurological one. The reset and the reckoning happen together. The confrontation of what has created such contractions in the mind and body is the very thing that will bring flexability in the body, and a healthy brain devoid of inflamation. 

In the days and weeks following an iboga treatment, participants typically describe a distinctive quality of experience: unusual clarity, emotional accessibility, a quieting of the habitual mental noise, a sense of being genuinely present in their own life in a way that had become foreign.

Cravings are often dramatically reduced or absent. The grey flatness of early recovery from opioids is frequently replaced by a genuine, sometimes surprising, capacity for engagement and pleasure.

This is the GDNF and BDNF at work.

This is the dopamine system beginning to repair. This is the neuroplasticity window, open and available for the integration work that follows.

This window does not stay open indefinitely. This is why integration, the psychological and lifestyle work done in the weeks and months after the treatment, is not optional.

The nervous system has been given a genuine opportunity to rewire.

What it rewires toward depends enormously on what you do with the opening.

The medicine creates the conditions. The work makes them permanent.